517 related articles for article (PubMed ID: 31561209)
21. Superiority of
Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
[TBL] [Abstract][Full Text] [Related]
22. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma.
Zhang X; Wakabayashi H; Hiromasa T; Kayano D; Kinuya S
Semin Nucl Med; 2023 Jul; 53(4):503-516. PubMed ID: 36641337
[TBL] [Abstract][Full Text] [Related]
23. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.
Timmers HJ; Taieb D; Pacak K
Horm Metab Res; 2012 May; 44(5):367-72. PubMed ID: 22399235
[TBL] [Abstract][Full Text] [Related]
24. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
25. Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.
Flynn A; Dwight T; Harris J; Benn D; Zhou L; Hogg A; Catchpoole D; James P; Duncan EL; Trainer A; Gill AJ; Clifton-Bligh R; Hicks RJ; Tothill RW
J Clin Endocrinol Metab; 2016 Mar; 101(3):1034-43. PubMed ID: 26796762
[TBL] [Abstract][Full Text] [Related]
26. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Hicks RJ; Hindié E; Guillet BA; Avram A; Ghedini P; Timmers HJ; Scott AT; Elojeimy S; Rubello D; Virgolini IJ; Fanti S; Balogova S; Pandit-Taskar N; Pacak K
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2112-2137. PubMed ID: 31254038
[TBL] [Abstract][Full Text] [Related]
27. Reduced uptake pattern on
de Jong MC; Pinto D; Parameswaran R
J Surg Oncol; 2023 Oct; 128(5):764-768. PubMed ID: 37403579
[TBL] [Abstract][Full Text] [Related]
28. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
29. From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.
Patel HV; Srivastava A; Becker MD; Beninato T; Laird AM; Singer EA
Curr Urol Rep; 2021 Jan; 22(1):2. PubMed ID: 33403502
[TBL] [Abstract][Full Text] [Related]
30. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Fischer A; Kloos S; Remde H; Dischinger U; Pamporaki C; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Bechmann N; Hantel C; Mohr H; Pellegata NS; Bornstein SR; Kroiss M; Auernhammer CJ; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
Eur J Endocrinol; 2023 Nov; 189(5):546-565. PubMed ID: 37949483
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
[TBL] [Abstract][Full Text] [Related]
32. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
33. Metabolic Subtyping of Pheochromocytoma and Paraganglioma by
van Berkel A; Vriens D; Visser EP; Janssen MJR; Gotthardt M; Hermus ARMM; Geus-Oei LF; Timmers HJLM
J Nucl Med; 2019 Jun; 60(6):745-751. PubMed ID: 30413658
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
35. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
[TBL] [Abstract][Full Text] [Related]
36. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine.
Burnichon N; Buffet A; Gimenez-Roqueplo AP
Curr Opin Oncol; 2016 Jan; 28(1):5-10. PubMed ID: 26599293
[TBL] [Abstract][Full Text] [Related]
37. Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.
Sait S; Pandit-Taskar N; Modak S
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28409892
[No Abstract] [Full Text] [Related]
38. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
Tang CYL; Chua WM; Huang HL; Lam WW; Loh LM; Tai D; Ong SYK; Yan SX; Loke KSH; Ng DC; Tham WY
J Neuroendocrinol; 2023 Dec; 35(12):e13349. PubMed ID: 37937484
[TBL] [Abstract][Full Text] [Related]
40. Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma.
Mak IYF; Hayes AR; Khoo B; Grossman A
Neuroendocrinology; 2019; 109(4):287-298. PubMed ID: 30856620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
